^
    over3years
    [VIRTUAL] A Phase 1b/2 Study of the BET inhibitor ZEN003694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations (SABCS 2020)
    Combination of ZEN003694 and talazoparib demonstrated anti-cancer activity in pretreated metastatic TNBC patients without gBRCA1/2 mutations. TCP is frequent but manageable with dose adjustments. PK is predictable, and PD data show meaningful target engagement.
    Clinical • P1/2 data • Combination therapy • BRCA Biomarker • PARP Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • RAD51 (RAD51 Homolog A) • IL1RN (Interleukin 1 receptor antagonist)
    |
    BRCA2 mutation • BRCA1 mutation • CXCL8 expression
    |
    Talzenna (talazoparib) • ZEN-3694 • ZEN-3219